A landmark study by Hyderabad’s L V Prasad Eye Institute (LVPEI), published in the British Journal of Ophthalmology, has ...

OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with ...

About OKYO OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain and dry eye disease, with ...

ZUG, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovations for ophthalmic and ...

ZUG, Switzerland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic ...

Source: Getty Images Avoiding and managing ocular radiotoxicity are increasingly important as more patients undergo radiotherapy for HNC, particularly uveal melanoma. Across all cancer types, ...

About The Study: The findings of this study suggest that semaglutide was not associated with an increased risk of eye disorders or diabetic retinopathy. Despite the fact that an association between ...

Indicators include persistent high corneal tactile sensitivity postanesthesia, reduced nerve density, and increased microneuroma density in central cornea. HealthDay News — In a study published in the ...

Argenx SE (NASDAQ:ARGX) stock is trading lower on Monday after the U.S. Food and Drug Administration (FDA) signaled serious risks/safety identified by the reporting system for Vyvgart Hytrulo ...

Glaucoma is a major cause of irreversible blindness, necessitating continuous improvements in imaging techniques for early detection and effective management. Recent advancements in optical coherence ...